A phase II randomized trial of gefitinib alone or with Tegafur/uracil treatment in patients with pulmonary adenocarcinoma who had failed previous chemotherapy

Yuh Min Chen, Wen Chien Fan, Chun Ming Tsai, Shih Hao Liu, Jen Fu Shih, Teh Ying Chou, Chieh Hung Wu, Kun Ta Chou, Yu Chin Lee, Reury Perng Perng, Jacqueline Whang-Peng

    Research output: Contribution to journalArticle

    23 Citations (Scopus)

    Abstract

    Background: Tegafur/uracil (UFT) is suitable for metronomic chemotherapy because of its underlying antiangiogenesis mechanism. This study aimed to assess the efficacy of adding daily oral UFT to gefitinib treatment in patients with pulmonary adenocarcinoma who had failed previous chemotherapy. Methods: Taiwanese patients who had adenocarcinoma of the lung and failed previous chemotherapy were randomized into gefitinib 250 mg daily alone (G) or plus daily oral UFT (GU). From November 2005 to August 2009, 115 patients were enrolled. Results: There were 58 patients in the G arm and 57 in the GU arm. One-year progression-free survival (PFS) was 18% in the G arm and 36.7% in the GU arm (p = 0.03). Fifty-four patients had tissue samples available for tumor epidermal growth factor receptor (EGFR) sequence analysis: 16 classical mutations and 8 wild types in the G arm, and 20 classical mutations and 10 wild-types in the GU arm. The addition of UFT significantly improved PFS in patients with EGFR mutations (14.4 versus 7.6 months, p = 0.0061). Forty-three patients underwent tumor tissue microvessel density measurement, and a trend favoring the addition of UFT to gefitinib treatment was found in those with low microvessel density (median PFS: 11.8 versus 2.8 months, p = 0.0536). The median survival time was 18.3 months in the G arm and 23.6 months in the GU arm (p = 0.381). Conclusion: Gefitinib plus UFT treatment had better PFS than gefitinib alone treatment. Gefitinib is effective in patients with EGFR mutations, and the addition of UFT treatment produced better PFS in these patients with mutations.

    Original languageEnglish
    Pages (from-to)1110-1116
    Number of pages7
    JournalJournal of Thoracic Oncology
    Volume6
    Issue number6
    DOIs
    Publication statusPublished - Jun 2011

    Fingerprint

    Tegafur
    Uracil
    Drug Therapy
    Disease-Free Survival
    Mutation
    Epidermal Growth Factor Receptor
    Therapeutics
    Microvessels
    gefitinib
    Adenocarcinoma of lung
    Sequence Analysis
    Neoplasms

    Keywords

    • Epidermal growth factor receptor (EGFR)
    • Gefitinib
    • Non-small cell lung cancer
    • Salvage therapy
    • UFT (tegafur/uracil)

    ASJC Scopus subject areas

    • Oncology
    • Pulmonary and Respiratory Medicine

    Cite this

    A phase II randomized trial of gefitinib alone or with Tegafur/uracil treatment in patients with pulmonary adenocarcinoma who had failed previous chemotherapy. / Chen, Yuh Min; Fan, Wen Chien; Tsai, Chun Ming; Liu, Shih Hao; Shih, Jen Fu; Chou, Teh Ying; Wu, Chieh Hung; Chou, Kun Ta; Lee, Yu Chin ; Perng, Reury Perng; Whang-Peng, Jacqueline.

    In: Journal of Thoracic Oncology, Vol. 6, No. 6, 06.2011, p. 1110-1116.

    Research output: Contribution to journalArticle

    Chen, Yuh Min ; Fan, Wen Chien ; Tsai, Chun Ming ; Liu, Shih Hao ; Shih, Jen Fu ; Chou, Teh Ying ; Wu, Chieh Hung ; Chou, Kun Ta ; Lee, Yu Chin ; Perng, Reury Perng ; Whang-Peng, Jacqueline. / A phase II randomized trial of gefitinib alone or with Tegafur/uracil treatment in patients with pulmonary adenocarcinoma who had failed previous chemotherapy. In: Journal of Thoracic Oncology. 2011 ; Vol. 6, No. 6. pp. 1110-1116.
    @article{62b499c749274b63a3165638fdf14083,
    title = "A phase II randomized trial of gefitinib alone or with Tegafur/uracil treatment in patients with pulmonary adenocarcinoma who had failed previous chemotherapy",
    abstract = "Background: Tegafur/uracil (UFT) is suitable for metronomic chemotherapy because of its underlying antiangiogenesis mechanism. This study aimed to assess the efficacy of adding daily oral UFT to gefitinib treatment in patients with pulmonary adenocarcinoma who had failed previous chemotherapy. Methods: Taiwanese patients who had adenocarcinoma of the lung and failed previous chemotherapy were randomized into gefitinib 250 mg daily alone (G) or plus daily oral UFT (GU). From November 2005 to August 2009, 115 patients were enrolled. Results: There were 58 patients in the G arm and 57 in the GU arm. One-year progression-free survival (PFS) was 18{\%} in the G arm and 36.7{\%} in the GU arm (p = 0.03). Fifty-four patients had tissue samples available for tumor epidermal growth factor receptor (EGFR) sequence analysis: 16 classical mutations and 8 wild types in the G arm, and 20 classical mutations and 10 wild-types in the GU arm. The addition of UFT significantly improved PFS in patients with EGFR mutations (14.4 versus 7.6 months, p = 0.0061). Forty-three patients underwent tumor tissue microvessel density measurement, and a trend favoring the addition of UFT to gefitinib treatment was found in those with low microvessel density (median PFS: 11.8 versus 2.8 months, p = 0.0536). The median survival time was 18.3 months in the G arm and 23.6 months in the GU arm (p = 0.381). Conclusion: Gefitinib plus UFT treatment had better PFS than gefitinib alone treatment. Gefitinib is effective in patients with EGFR mutations, and the addition of UFT treatment produced better PFS in these patients with mutations.",
    keywords = "Epidermal growth factor receptor (EGFR), Gefitinib, Non-small cell lung cancer, Salvage therapy, UFT (tegafur/uracil)",
    author = "Chen, {Yuh Min} and Fan, {Wen Chien} and Tsai, {Chun Ming} and Liu, {Shih Hao} and Shih, {Jen Fu} and Chou, {Teh Ying} and Wu, {Chieh Hung} and Chou, {Kun Ta} and Lee, {Yu Chin} and Perng, {Reury Perng} and Jacqueline Whang-Peng",
    year = "2011",
    month = "6",
    doi = "10.1097/JTO.0b013e3182121c09",
    language = "English",
    volume = "6",
    pages = "1110--1116",
    journal = "Journal of Thoracic Oncology",
    issn = "1556-0864",
    publisher = "International Association for the Study of Lung Cancer",
    number = "6",

    }

    TY - JOUR

    T1 - A phase II randomized trial of gefitinib alone or with Tegafur/uracil treatment in patients with pulmonary adenocarcinoma who had failed previous chemotherapy

    AU - Chen, Yuh Min

    AU - Fan, Wen Chien

    AU - Tsai, Chun Ming

    AU - Liu, Shih Hao

    AU - Shih, Jen Fu

    AU - Chou, Teh Ying

    AU - Wu, Chieh Hung

    AU - Chou, Kun Ta

    AU - Lee, Yu Chin

    AU - Perng, Reury Perng

    AU - Whang-Peng, Jacqueline

    PY - 2011/6

    Y1 - 2011/6

    N2 - Background: Tegafur/uracil (UFT) is suitable for metronomic chemotherapy because of its underlying antiangiogenesis mechanism. This study aimed to assess the efficacy of adding daily oral UFT to gefitinib treatment in patients with pulmonary adenocarcinoma who had failed previous chemotherapy. Methods: Taiwanese patients who had adenocarcinoma of the lung and failed previous chemotherapy were randomized into gefitinib 250 mg daily alone (G) or plus daily oral UFT (GU). From November 2005 to August 2009, 115 patients were enrolled. Results: There were 58 patients in the G arm and 57 in the GU arm. One-year progression-free survival (PFS) was 18% in the G arm and 36.7% in the GU arm (p = 0.03). Fifty-four patients had tissue samples available for tumor epidermal growth factor receptor (EGFR) sequence analysis: 16 classical mutations and 8 wild types in the G arm, and 20 classical mutations and 10 wild-types in the GU arm. The addition of UFT significantly improved PFS in patients with EGFR mutations (14.4 versus 7.6 months, p = 0.0061). Forty-three patients underwent tumor tissue microvessel density measurement, and a trend favoring the addition of UFT to gefitinib treatment was found in those with low microvessel density (median PFS: 11.8 versus 2.8 months, p = 0.0536). The median survival time was 18.3 months in the G arm and 23.6 months in the GU arm (p = 0.381). Conclusion: Gefitinib plus UFT treatment had better PFS than gefitinib alone treatment. Gefitinib is effective in patients with EGFR mutations, and the addition of UFT treatment produced better PFS in these patients with mutations.

    AB - Background: Tegafur/uracil (UFT) is suitable for metronomic chemotherapy because of its underlying antiangiogenesis mechanism. This study aimed to assess the efficacy of adding daily oral UFT to gefitinib treatment in patients with pulmonary adenocarcinoma who had failed previous chemotherapy. Methods: Taiwanese patients who had adenocarcinoma of the lung and failed previous chemotherapy were randomized into gefitinib 250 mg daily alone (G) or plus daily oral UFT (GU). From November 2005 to August 2009, 115 patients were enrolled. Results: There were 58 patients in the G arm and 57 in the GU arm. One-year progression-free survival (PFS) was 18% in the G arm and 36.7% in the GU arm (p = 0.03). Fifty-four patients had tissue samples available for tumor epidermal growth factor receptor (EGFR) sequence analysis: 16 classical mutations and 8 wild types in the G arm, and 20 classical mutations and 10 wild-types in the GU arm. The addition of UFT significantly improved PFS in patients with EGFR mutations (14.4 versus 7.6 months, p = 0.0061). Forty-three patients underwent tumor tissue microvessel density measurement, and a trend favoring the addition of UFT to gefitinib treatment was found in those with low microvessel density (median PFS: 11.8 versus 2.8 months, p = 0.0536). The median survival time was 18.3 months in the G arm and 23.6 months in the GU arm (p = 0.381). Conclusion: Gefitinib plus UFT treatment had better PFS than gefitinib alone treatment. Gefitinib is effective in patients with EGFR mutations, and the addition of UFT treatment produced better PFS in these patients with mutations.

    KW - Epidermal growth factor receptor (EGFR)

    KW - Gefitinib

    KW - Non-small cell lung cancer

    KW - Salvage therapy

    KW - UFT (tegafur/uracil)

    UR - http://www.scopus.com/inward/record.url?scp=79958120436&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=79958120436&partnerID=8YFLogxK

    U2 - 10.1097/JTO.0b013e3182121c09

    DO - 10.1097/JTO.0b013e3182121c09

    M3 - Article

    VL - 6

    SP - 1110

    EP - 1116

    JO - Journal of Thoracic Oncology

    JF - Journal of Thoracic Oncology

    SN - 1556-0864

    IS - 6

    ER -